Page last updated: 2024-11-02

palmidrol and Irritable Bowel Syndrome

palmidrol has been researched along with Irritable Bowel Syndrome in 2 studies

palmidrol: a cannabinoid receptor-inactive eCB-related molecule used as prophylactic in helping to prevent respiratory viral infection
palmitoyl ethanolamide : An N-(long-chain-acyl)ethanolamine that is the ethanolamide of palmitic (hexadecanoic) acid.

Irritable Bowel Syndrome: A disorder with chronic or recurrent colonic symptoms without a clearcut etiology. This condition is characterized by chronic or recurrent ABDOMINAL PAIN, bloating, MUCUS in FECES, and an erratic disturbance of DEFECATION.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Capasso, R1
Orlando, P1
Pagano, E1
Aveta, T1
Buono, L1
Borrelli, F1
Di Marzo, V2
Izzo, AA1
Cremon, C1
Stanghellini, V1
Barbaro, MR1
Cogliandro, RF1
Bellacosa, L1
Santos, J1
Vicario, M1
Pigrau, M1
Alonso Cotoner, C1
Lobo, B1
Azpiroz, F1
Bruley des Varannes, S1
Neunlist, M1
DeFilippis, D1
Iuvone, T1
Petrosino, S1
Barbara, G1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Effect of the Oral Administration in IBS Patients of the Association of 200 mg Micronised Palmitoylethanolamide (PEA) and 20 mg Polydatin, on Parameters of Intestinal Inflammation and Visceral Hyperalgesia.[NCT01370720]Phase 260 participants (Anticipated)Interventional2010-02-28Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trials

1 trial available for palmidrol and Irritable Bowel Syndrome

ArticleYear
Randomised clinical trial: the analgesic properties of dietary supplementation with palmitoylethanolamide and polydatin in irritable bowel syndrome.
    Alimentary pharmacology & therapeutics, 2017, Volume: 45, Issue:7

    Topics: Abdominal Pain; Adult; Amides; Analgesics; Cell Count; Dietary Supplements; Double-Blind Method; Eth

2017

Other Studies

1 other study available for palmidrol and Irritable Bowel Syndrome

ArticleYear
Palmitoylethanolamide normalizes intestinal motility in a model of post-inflammatory accelerated transit: involvement of CB₁ receptors and TRPV1 channels.
    British journal of pharmacology, 2014, Volume: 171, Issue:17

    Topics: Amides; Animals; Colitis; Disease Models, Animal; Ethanolamines; Gastrointestinal Motility; Inflamma

2014